OKYO OKYO Pharma Ltd

NEUTRAL Impact: 2/10 3
Horizon immediate Filed Jun 1, 2026 Processed 11d 9h ago SEC 0001493152-26-026685
Form 3 — initial insider ownership statement
Latest settled — T+1d ⚠ clustered
OKYO ▼ -2.35% at T+1d
NEUTRAL call ✗ call lost -2.35% · α vs SPY -1.63% · entry $1.70 → $1.66
Next anchor: T+5d due 5d ago
Currently $1.52 · -10.59% from $1.70 entry
Entry anchored
Jun 1, 2026
via day open
T+1d
-2.35%
call -2.35% · α -1.63%
$1.66
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

John P. Brancaccio filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing his holdings in OKYO Pharma Ltd as of March 18, 2026. He reported 30,201 shares of common stock and a large number of vested and unvested stock options with exercise prices ranging from $1.46 to $2.13, expiring between 2033 and 2035. This is a routine initial ownership disclosure for a new insider and contains no trading activity or material corporate event.

Actionable Insight

This Form 3 is a standard initial ownership filing for a new insider and carries no trading signal. Monitor for any future Form 4 filings that would indicate open-market buying or selling by Brancaccio, which could provide a more actionable signal on insider sentiment.

Key Facts

  • John P. Brancaccio filed Form 3 as an initial statement of beneficial ownership.
  • Brancaccio directly owns 30,201 shares of OKYO Pharma common stock.
  • He holds multiple tranches of stock options exercisable for common stock, with exercise prices between $1.46 and $2.13, expiring from 2033 to 2035.
  • The filing is dated as of March 18, 2026, and was submitted on June 1, 2026.
  • No open-market purchases or sales are reported; this is a disclosure of existing holdings.

Financial Impact

No financial impact; the filing is a routine insider ownership disclosure with no transaction or corporate action.

Risk Factors

  • No material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001493152-26-026685
Document: 0001493152-26-026685-index.html0001493152-26-026685
Document: 0001493152-26-026685.txt0001493152-26-026685
8 reports for OKYO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for OKYO — sortable, filterable
Type Now
Jun 2, 2026
10d ago
3
NEUTRAL ★ 2/10
$1.66 $1.68▲ +1.20%▲ +0.81%$1.52 (−8.43%)
Jun 1, 2026
11d ago
3
NEUTRAL ★ 2/10
$1.70 $1.66▼ −2.35%▼ −1.63%$1.52 (−10.59%)
Jun 1, 2026
11d ago
3
NEUTRAL ★ 2/10
$1.70 $1.66▼ −2.35%▼ −1.63%$1.52 (−10.59%)
May 19, 2026
24d ago
6-K
NEUTRAL ★ 3/10
$1.60 $1.60· 0.00%▼ −1.04%$1.52 (−5.00%)
Apr 7, 2026
9w ago
6-K
BULLISH ★ 7/10
$1.60 $1.59▼ −0.63%▼ −3.16%$1.52 (−5.00%)
Apr 7, 2026
9w ago
Press Release
NEUTRAL ★ 4/10
$1.60 $1.59▼ −0.63%▼ −3.16%$1.52 (−5.00%)
Mar 19, 2026
12w ago
Press Release
NEUTRAL ★ 3/10
$1.62 $1.57▼ −3.09%▼ −1.34%$1.52 (−6.17%)
Mar 19, 2026
12w ago
Press Release
NEUTRAL ★ 4/10
$1.62 $1.57▼ −3.09%▼ −1.34%$1.52 (−6.17%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (53h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access